Project Grant K23EY036491
- This federal Project Grant award from the National Eye Institute (CFDA 93.867 Vision Research) provides $233,736.00 in funding to the University of California, San Diego (UCSD) to conduct research on regulating the insulin-like growth factor 1 receptor (IGF-1R) in acute and chronic thyroid eye disease (TED). The study aims to determine the cell type expression of IGF-1R in acute and chronic TED, and investigate the regulation of IGF-1R expression through cis-regulatory elements and CRISPR...
- This $348,800 Project Grant was awarded on September 30, 2025 by the National Eye Institute (NEI), under the Vision Research federal grant program (CFDA 93.867), to N'Waii Inc. in Chicago, Illinois. The grant supports the development of a first-in-class mitochondrially targeted antioxidant drug candidate for the treatment of dry eye disease (DED), a condition affecting 20% of the global adult population. The drug candidate exhibits potent free radical scavenging capabilities and has demonstrated...
- This $231,000 Project Grant award from the National Eye Institute (NEI), under the federal Vision Research program (CFDA 93.867), will fund the development of a generalized deep learning platform to improve the objectivity, reproducibility, and accuracy of quantifying and assessing experimental autoimmune uveitis (EAU) - a valuable animal disease model for studying human uveitis. The project aims to generate high-quality, well-annotated multi-modal datasets from three independent research...
- This $257,785 Project Grant was awarded on April 1, 2025 by the National Eye Institute (NEI) under the Vision Research federal grant program (CFDA 93.867). The grant supports the development of a refillable micromachined lens capsule-based drug delivery device for extended intraocular delivery of biologics and immune-modulating peptides to treat non-infectious uveitis. The key products/services to be delivered under this 4-year grant include: Characterizing and controlling the release of the...
- The National Eye Institute (NEI), under the U.S. Department of Health and Human Services, awarded a $321,904 Project Grant to Proteris Biotech, Inc. through the Vision Research federal grant program (CFDA 93.867). The award, spanning August 1, 2025 to July 31, 2026, will fund the early development of the natural tear protein clusterin (CLU) as a novel approach to treat dry eye disease. The research aims to conduct non-GMP stability analysis of the drug substance and product, as well as perform...
- This Project Grant award of $492,000.00 from the National Eye Institute (CFDA 93.867 - Vision Research) supports a study on decentralized approaches to investigating evaporative dry eye disease (DED). The key products and services to be delivered under this award include: Developing a remote trial design to allow for decentralized recruitment and study of DED, including an operations manual and statistical analysis plan. Determining the feasibility and utility of obtaining transcriptomic...
- This Project Grant award of $375,940 from the National Eye Institute (NEI) under the Vision Research federal grant program (CFDA 93.867) aims to conduct a feasibility study for using the NeuroVEP system developed by Neurofieldz Inc. to provide objective diagnostic information on neuro-ophthalmic diseases affecting the afferent visual system. The key products or services to be delivered under this Phase I Small Business Innovation Research (SBIR) project include: 1) Developing custom tests for...
- The National Eye Institute (NEI) awarded a $896,046 project grant to The Schepens Eye Research Institute, Inc. in Boston, MA, under the Vision Research federal grant program (CFDA 93.867). The project, titled "Non-Invasive Electrical Stimulation as a Therapy for Diabetic Keratopathy", focuses on exploring the effectiveness of non-invasive transpalpebral electrical stimulation (TPES) as a treatment for diabetic keratopathy, a common complication in individuals with diabetes that results...
- This Project Grant award from the National Eye Institute (CFDA 93.867 - Vision Research) supports the development of a novel, noninvasive, and sensitive diagnostic method to measure retinal dysfunction. The $491,466 award will fund research at the University of California, San Francisco (UCSF) from January 1, 2025 to December 31, 2026. The project aims to create a scalable diagnostic tool that can detect the earliest signs of retinal diseases like diabetic retinopathy and retinitis pigmentosa,...
- This Project Grant award from the National Eye Institute's Vision Research program (CFDA 93.867) provides $179,964 to the University of California, Irvine (UCI) to develop innovative biomarkers for optic neuropathies using deep learning-based analysis of optical coherence tomography (OCT) imagery. The project aims to overcome limitations of current OCT-based diagnostics by employing advanced computational techniques like deep learning, neural fields, and geometric modeling to enhance the...
This $257,920 Project Grant was awarded by the National Eye Institute (NEI), part of the National Institutes of Health, under the Vision Research federal grant program (CFDA 93.867). The grant aims to use Spatial Frequency Domain Imaging (SFDI) to non-invasively identify optical tissue properties related to vascular congestion and tissue edema in patients with Thyroid Eye Disease (TED). The research, led by Dr. Ediriwickrema at the University of California, Irvine, will establish an optical signature profile for TED patients receiving the IGF1R inhibitor drug teprotumumab. The project will also conduct clinical pathology correlations on surgical specimens from healthy and TED patients. This 3-year grant, awarded on September 15, 2025, supports the development of noninvasive diagnostic and therapeutic response metrics for TED and similar inflammatory conditions.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $257.9k | 9/10/25 |